How big is Rhythm Pharmaceuticals, Inc.?

As of Jun 18, Rhythm Pharmaceuticals, Inc. has a market capitalization of $3.94 billion, with net sales of $136.86 million and a net profit of -$168.69 million over the last four quarters. Shareholder's funds are $21.73 million, and total assets amount to $393.47 million.

As of Jun 18, Rhythm Pharmaceuticals, Inc. has a market capitalization of 3,942.62 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 136.86 million, while the sum of Net Profit for the same period is -168.69 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 21.73 million and Total Assets at 393.47 million.

What does Rhythm Pharmaceuticals, Inc. do?

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company that develops peptide therapeutics for rare genetic metabolic disorders. As of March 2025, it reported net sales of $33 million and a net loss of $49 million, with a market cap of approximately $3.94 billion.

Overview: <BR>Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for rare genetic deficiencies that lead to life-threatening metabolic disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 33 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -49 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,942.62 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.20 <BR>Return on Equity: -926.82% <BR>Price to Book: 208.09<BR><BR>Contact Details: <BR>Address: 222 Berkeley St Fl 12, BOSTON MA: 02116-3733 <BR>Tel: ['1 857 2644280', '1 212 3621200'] <BR>Fax: 1 857 2644299 <BR>Website: http://www.rhythmtx.com

Should I buy, sell or hold Rhythm Pharmaceuticals, Inc.?

Who are in the management team of Rhythm Pharmaceuticals, Inc.?

As of March 2022, Rhythm Pharmaceuticals' management team is led by Dr. David Meeker as Chairman, President, and CEO, alongside a diverse Board of Directors that includes Dr. Camille Bedrosian, Mrs. Lynn Tetrault, Mr. Stuart Arbuckle, Mr. Todd Foley, and Ms. Jennifer Good.

As of March 2022, the management team of Rhythm Pharmaceuticals, Inc. includes Dr. David Meeker, who serves as the Chairman of the Board, President, and Chief Executive Officer. Other members of the Board of Directors are Dr. Camille Bedrosian, Mrs. Lynn Tetrault, Mr. Stuart Arbuckle, Mr. Todd Foley, and Ms. Jennifer Good, all of whom hold various director positions. <BR><BR>In summary, the key management personnel are Dr. David Meeker, along with a diverse board consisting of both independent and non-independent directors.

Is Rhythm Pharmaceuticals, Inc. overvalued or undervalued?

As of November 2, 2021, Rhythm Pharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics, including a Price to Book Value of 228.70 and a P/E ratio of -36.41, despite a strong year-to-date return of 76.03%.

As of 2 November 2021, the valuation grade for Rhythm Pharmaceuticals, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial stability. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 228.70, an EV to EBIT of -24.75, and an EV to EBITDA of -24.97. These ratios suggest that the company is struggling to generate positive earnings relative to its valuation.<BR><BR>In comparison to its peers, Rhythm Pharmaceuticals, Inc. has a P/E ratio of -36.41, which is significantly worse than Merus NV at -13.18 and CymaBay Therapeutics, Inc. at -35.38, highlighting its relative overvaluation in the market. Despite its strong year-to-date return of 76.03% compared to the S&P 500's 12.22%, this performance does not mitigate the concerns raised by its negative financial ratios, reinforcing the conclusion that the company is overvalued.

Is Rhythm Pharmaceuticals, Inc. technically bullish or bearish?

As of October 24, 2025, Rhythm Pharmaceuticals, Inc. is in a bullish trend with strong momentum indicators, despite some bearish signals in RSI and KST, and has significantly outperformed the S&P 500 with a year-to-date return of 97.34%.

As of 24 October 2025, the technical trend for Rhythm Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands also indicate bullishness across both time frames. The daily moving averages confirm a bullish stance. However, the weekly and monthly RSI readings are bearish, suggesting some weakness in momentum. The KST is mildly bearish on both weekly and monthly charts, and Dow Theory shows no trend weekly but is bullish monthly. Overall, the stock is currently bullish, driven by strong momentum indicators despite some bearish signals in RSI and KST.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 across all periods, with a year-to-date return of 97.34% compared to the S&P 500's 15.47%, and a one-year return of 122.23% versus 16.90%.